Iambic Provides Business Updates and Third Quarter 2026 Financial ResultsGlobeNewswire Nov 16, 2026, 1:00:00 PM
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven CancersBusiness Wire Oct 26, 2026, 12:00:00 PM